The Oxford based company had been expecting an investment of around fifty million for developing various neuro therapeutic drugs isolated from psychedelics. However, proceeds have exceeded expectations with a net amount of eighty million being pumped into its venture. The company reports that its main priority will be to create low dose psilocybin drugs to cure neuralgiform headaches which affect a substantial part of the European and American Population. The amount will also be utilised in trials of a nasal drug that might prove vital in eradicating treatment resistant depression.
Dimethyltryptamine (DPT) Conference to be organised by the Microdose Psychedelic Insights
The Microdose Psychedelic Insights has convened a virtual conference session to debate and discuss about what they believe is the newest elephant in the room - The DPT. The utility of DPT with respect to recuperative and therapeutic care and it's position in the market and biopharmaceutical industry is a subject of great conjecture. The conference will be organized for two days, starting September ninth. Its a part of Microdose's Molecular masterclass conference series that aims to raise awareness about the various psychedelics and psychoactive substances that have been discovered by researchers.
Comentários